# ClinicalTrials.gov record NCT03456687

> PeptideScanner retained ClinicalTrials.gov record NCT03456687 at 2026-07-30T19:35:26.142Z. Its registry update date was 2022-09-16, and PeptideScanner's reviewed identity mapping was exenatide.

- Evidence object: `story:clinicaltrials-gov-nct03456687-exenatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-09-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03456687-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03456687-exenatide-v1.json
- Content SHA-256: `84ecd0449122900b9043cec8003c02b390e83152c257436c2104717170f1a125`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03456687 ([`ctg-observation-nct03456687-2022-09-16-596d8102a1cb`](#source-ctg-observation-nct03456687-2022-09-16-596d8102a1cb))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03456687 at 2026-07-30T19:35:26.142Z. Its registry update date was 2022-09-16, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct03456687-2022-09-16-596d8102a1cb`](#source-ctg-observation-nct03456687-2022-09-16-596d8102a1cb))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03456687 at 2026-07-30T19:35:26.142Z. Its registry update date was 2022-09-16, and PeptideScanner's reviewed identity mapping was exenatide. ([`ctg-observation-nct03456687-2022-09-16-596d8102a1cb`](#source-ctg-observation-nct03456687-2022-09-16-596d8102a1cb))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03456687-2022-09-16-596d8102a1cb`](#source-ctg-observation-nct03456687-2022-09-16-596d8102a1cb))

## Sources

<a id="source-ctg-observation-nct03456687-2022-09-16-596d8102a1cb"></a>
- **ClinicalTrials.gov record NCT03456687 · retained source version 2022-09-16:596d8102a1cb6014bd8929e5f65d9b310664ed67702ed776130faee35a133f68** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03456687) (`ctg-observation-nct03456687-2022-09-16-596d8102a1cb`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03456687." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03456687-exenatide-v1.json SHA-256: 84ecd0449122900b9043cec8003c02b390e83152c257436c2104717170f1a125.